Corteva(US:CTVA) Jing Ji Guan Cha Wang·2026-02-12 14:11Company Developments - Corteva's board approved a plan to split the company into two independent publicly traded entities, expected to be completed in the second half of 2026. "New Corteva" will focus on crop protection (including biopesticides), while "SpinCo" will concentrate on seeds and emerging technologies such as gene editing and biofuels [2] Product Development Progress - The company plans to launch the biostimulant seed treatment Lumidapt Valta LS in the U.S. market for the 2026 planting season, which has completed the regulatory approval phase and aims to enhance crop yields [3] Performance Strategy - Corteva provided preliminary performance outlook for 2026, expecting a midpoint of $4.18 billion in earnings before interest, taxes, depreciation, and amortization (EBITDA), reflecting the company's confidence in its growth potential [4] Strategic Initiatives - Corteva has established a multi-year collaboration with Profluent Bio to leverage AI technologies, such as the OpenCRISPR-1 genome editing tool, to accelerate the development of resilient and high-yield crop varieties, which may drive long-term innovation [5]